{"entity":{"id":"tqb6411","kind":"drug","name":"TQB6411","aka":[],"tldr":"TQB6411 is an experimental antibody-drug conjugate from Chia Tai Tianqing Pharmaceutical in phase 2 trials for non-small-cell lung cancer and oesophageal cancer, aimed at EGFR and MET.","summary":"TQB6411 is an antibody-drug conjugate developed by Chia Tai Tianqing Pharmaceutical. Its targets are EGFR and MET. ClinicalTrials.gov describes the intervention as: TQB6411 for Injection is administered every 21 days as a treatment cycle. TQB6411 for injection is administered every 28 days as a treatment cycle. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, in non-small-cell lung cancer and oesophageal cancer. The largest, NCT07367529, plans to enrol 465 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of TQB6411","url":"https://clinicaltrials.gov/search?intr=TQB6411"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","esophageal"],"sections":[],"technologies":[],"targets":["egfr","met"],"drugs":[],"companies":["sino-biopharm"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07367516","nct07367529"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"ADC","mechanism":"Antibody-drug conjugate directed at EGFR and MET, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/tqb6411/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"sino-biopharm","kind":"company","name":"Sino Biopharmaceutical (Chia Tai Tianqing)","route":"/companies/sino-biopharm/"}],"trial":[{"id":"nct07367529","kind":"trial","name":"A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection","route":"/trials/nct07367529/"},{"id":"nct07367516","kind":"trial","name":"Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer","route":"/trials/nct07367516/"}]}}